Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06522828
PHASE2

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.

Official title: A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2024-10-10

Completion Date

2026-08

Last Updated

2024-10-21

Healthy Volunteers

No

Interventions

DRUG

SSGJ-707

SSGJ-707 is a bispecific antibody against human PD-1 and VEGF

DRUG

carboplatin

chemotherapy

DRUG

paclitaxel

chemotherapy

Locations (1)

Chongqing Cancer Hospital

Chongqing, China